ProCE Banner Activity

Immunotherapy: An Intriguing Work in Progress for the Treatment of Advanced SCLC

Clinical Thought
Second-line therapy options are limited for advanced SCLC. Are immunotherapy regimens safe and efficacious enough to consider for this patient population?

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Bristol Myers Squibb